Imagine visiting your doctor because of persistent bloating or unexplained abdominal discomfort, only to discover that a simple blood sample could help identify whether something far more serious is happening inside your body. That possibility is now being investigated in a major NHS research trial involving more than 20,000 patients across England.
Cancer does not always announce its arrival with a dramatic warning. Sometimes, the earliest signs are remarkably ordinary: a stomach that feels uncomfortable, persistent bloating, unexplained abdominal pain or changes that are easy to dismiss as digestive problems.
For doctors, this creates a difficult challenge. These symptoms are common and usually have non-cancerous explanations. Yet, in some patients, they may be the first indication of a serious disease.
Now, researchers at the University of Birmingham are investigating whether advanced blood-testing technologies could help GPs recognise these warning signals earlier.
The trial, called STRIDE-RCT, will involve more than 20,000 NHS patients aged 45 and above, recruited through at least 200 GP practices in England. It will evaluate blood tests designed to identify signals associated with 13 different cancers.
The ambition is significant: help doctors determine which patients need further investigation without sending everyone with common abdominal symptoms through unnecessary hospital referrals.
But there is an important question. Can a few tubes of blood really help doctors identify so many different cancers?
Thirteen cancers, one research programme: What will the NHS investigate?
The STRIDE-RCT trial is being led by the University of Birmingham, with government funding of up to £8.49 million through the Office for Life Sciences and the National Institute for Health and Care Research (NIHR).
The cancers being investigated include:
-
Bowel cancer
-
Small bowel cancer
-
Stomach cancer
-
Oesophageal cancer
-
Pancreatic cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Ovarian cancer
-
Endometrial cancer
-
Kidney cancer
-
Bladder cancer
-
Prostate cancer
These diseases can be particularly challenging to identify during their earlier stages because their symptoms may overlap with common digestive or abdominal conditions.
According to the University of Birmingham, approximately 71,000 people in England are diagnosed annually with pancreatic, stomach, liver, ovarian or bowel cancer, with nearly 35,000 deaths associated with these cancers.
The research aims to give GPs another way to distinguish patients who may need urgent investigation from those whose symptoms are more likely to have a less serious cause.
Read the University of Birmingham’s official announcement.
How can a blood sample reveal cancer?
The science behind these tests is particularly interesting because cancer can leave molecular clues in the bloodstream long before a conventional diagnosis is established.
Different technologies look for different biological signals.
1. Circulating tumour DNA
Cancer cells can release tiny fragments of their genetic material into the bloodstream. These fragments are known as circulating tumour DNA, or ctDNA.
By analysing these fragments, researchers may be able to identify molecular signatures associated with cancer.
One example is Natera’s Signatera technology, which uses tumour-informed analysis to identify cancer-associated DNA fragments. Its established applications include monitoring for molecular residual disease and recurrence in selected cancers.
2. Cancer-related proteins and biomarkers
Some tests investigate patterns of proteins, amino acids and other biological molecules that may change when cancer develops.
Rather than relying on one isolated marker, advanced approaches can analyse several signals together.
For example, the PinPoint AI technology evaluates multiple biomarkers, combining their information to produce a risk assessment.
3. Extracellular vesicles
Cells release tiny membrane-bound particles called extracellular vesicles. These can carry proteins and other molecular material reflecting activity within their cells of origin.
Mercy Bioanalytics’ Halo technology examines individual extracellular vesicles for cancer-associated signals.
These different approaches could help identify biological changes that ordinary blood investigations might miss.
However, detecting a suspicious molecular signal is not the same as proving that someone has cancer. Each technology must demonstrate that it can identify disease reliably in the real-world clinical setting.
Why this trial could matter so much to GPs
One of the biggest challenges in cancer diagnosis is deciding which patients need further investigation.
Consider someone aged 52 who visits their GP complaining of persistent bloating and abdominal discomfort.
The symptoms could indicate digestive problems, food intolerance, inflammation or numerous other conditions. Cancer is only one possibility.
Currently, doctors must combine medical history, physical examination, routine blood investigations and clinical judgement to decide whether further testing is necessary.
The new blood-testing approaches could provide additional information during this decision-making process.
The ambition is not to replace doctors or eliminate established diagnostic procedures. Instead, researchers want to determine whether these tests can help GPs identify higher-risk patients sooner and reduce unnecessary referrals.
Professor Aneel Bhangu, one of the trial’s co-chief investigators, has highlighted the difficulty of distinguishing common abdominal symptoms from early cancer.
The trial will assess how these technologies perform alongside ordinary GP assessment.
The UK Government’s announcement explains the trial’s objectives and funding.
The biggest challenge: Will the tests actually save lives?
There is a difference between detecting a cancer signal and demonstrating that earlier detection improves survival.
A blood test might identify a suspicious biological marker, but doctors still need to establish whether cancer is present, where it originated and what stage it has reached.
False positives are another concern. An abnormal result could lead to additional scans, biopsies, anxiety and unnecessary investigations. False negatives are equally important because a reassuring result must never create a false sense of security.
This is why the NHS trial matters. Researchers need to understand not just whether the tests detect cancer, but how accurately they perform in everyday general practice.
There is also an important distinction between this research and universal cancer screening. STRIDE-RCT is recruiting people aged 45 and above who already have abdominal symptoms. It is not offering a routine cancer test to the entire healthy population.
Previous research demonstrates why careful evaluation matters. The separate NHS-Galleri trial, involving more than 142,000 volunteers, did not meet its primary objective of reducing the overall number of stage 3 and stage 4 cancers diagnosed. Its results underline why promising blood tests need rigorous clinical evidence before widespread adoption.
Read the UCLH report on the Galleri trial results.
Could this change cancer diagnosis around the world?
If the STRIDE-RCT results demonstrate that these tests are accurate, safe and clinically useful, their implications could extend beyond England.
Healthcare systems worldwide face a similar problem: identifying serious diseases when patients initially present with symptoms that could have dozens of explanations.
A relatively simple blood test that helps doctors decide who needs further investigation could potentially improve diagnostic pathways, particularly for cancers that are difficult to recognise early.
For countries such as India, where access to specialist investigations can be uneven, affordable and reliable early-detection technologies could eventually be particularly valuable. However, their usefulness would depend on cost, availability, validation in local populations and access to follow-up treatment.
For now, the NHS research remains an important step towards answering a question that cancer researchers have been pursuing for years.
A small blood sample, a much bigger possibility
Cancer diagnosis has traditionally depended on identifying suspicious symptoms, examining affected organs and confirming disease through imaging, endoscopy or tissue biopsy.
But the bloodstream may contain clues that help doctors recognise trouble earlier in that process.
The STRIDE-RCT trial is testing whether those clues can be turned into something practical for everyday medicine.
It is too early to call this a breakthrough, and nobody should mistake participation in the trial for access to a guaranteed cancer-detection test.
Yet the possibility is compelling.
What if the first warning that cancer is developing is not a visible tumour, persistent pain or a dramatic change in someone’s health, but a tiny molecular signal circulating quietly through their blood?
Finding that signal reliably could give doctors something incredibly valuable: more time to investigate, more opportunities to diagnose disease earlier and potentially more chances to treat cancer before it becomes harder to control.
